共 48 条
- [41] Final results and pharmacoeconomic analysis of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): A phase II randomised study by the European Lung Cancer Working PartyLUNG CANCER, 2012, 77 (03) : 605 - 610Berghmans, T.Lafitte, J. J.Giner, V.Berchier, M. C.Scherpereel, A.Lewin, D.Paesmans, M.Meert, A. P.Bosschaerts, T.Leclercq, N.Sculier, J. P.
- [42] FINAL RESULTS AND PHARMACOECONOMIC ANALYSIS OF A TRIAL COMPARING TWO NEOADJUVANT CHEMOTHERAPY (CT) REGIMENS FOLLOWED BY SURGERY IN PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II RANDOMISED STUDY BY THE EUROPEAN LUNG CANCER WORKING PARTYJOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S465 - S466Berghmans, ThierryLafitte, Jean-JacquesGiner, VicenteBerchier, Marie-ClaudeScherpereel, ArnaudLewin, DanielPaesmans, MarianneMeert, Anne-PascaleBosschaerts, ThierryLeclercq, NathalieSculier, Jean-Paul
- [43] Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic RegimensJOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : 149 - 156Valero, VicenteForbes, JohnPegram, Mark D.Pienkowski, TadeuszEiermann, Wolfgangvon Minckwitz, GunterRoche, HenriMartin, MiguelCrown, JohnMackey, John R.Fumoleau, PierreRolski, JanuszMrsic-Krmpotic, ZrinkaJagiello-Gruszfeld, AgnieszkaRiva, AlessandroBuyse, MarcTaupin, HenrySauter, GuidoPress, Michael F.Slamon, Dennis J.
- [44] ISEL: a Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimensLUNG CANCER, 2005, 49 : S4 - S4Thatcher, NChang, AParikh, PPemberton, KArcher, V
- [45] A phase I multicenter study of antroquinonol in patients with metastatic non-small-cell lung cancer who have received at least two prior systemic treatment regimens, including one platinum-based chemotherapy regimenMOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (06) : 1375 - 1380Lee, Yu-ChinHo, Ching-LiangLaw, Woei-YauChen, Yuh-Min
- [46] HELOISE: phase IIIB randomized multicenter study comparing two trastuzumab (H) dose regimens combined with chemotherapy (CT) as first-line (1L) therapy in patients (pts) with HER2-positive metastatic gastric/gastroesophageal junction adenocarcinoma (mGC/GEJC)CANCER RESEARCH, 2016, 76Shah, Manish A.Xu, RuihuaBang, Yung-JueHoff, Paulo M.Liu, TianshuHerraez-Baranda, Luis A.Xia, FanGarg, AmitShing, MonaTabernero, Josep
- [47] Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219LUNG CANCER, 2019, 133 : 48 - 55Melosky, BarbaraBradbury, PenelopeTu, DongshengFlorescu, MarieReiman, AnthonyNicholas, GarthBasappa, NaveenRothenstein, JeffreyGoffin, John R.Laurie, Scott A.Wheatley-Price, PaulLeighl, NatashaGoss, GlenwoodReaume, M. NeilButts, CharlesMurray, NevinCard, CynthiaKo, JennyBlais, NormandGray, SamanthaLui, HongboBrown-Walker, PamelaKaurah, PardeepPrentice, Leah M.Seymour, Lesley
- [48] Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapyBMJ OPEN, 2020, 10 (12):Minatogawa, HirokoIzawa, NaokiKawaguchi, TakashiMiyaji, TempeiShimomura, KazuhiroKazunori, HondaIihara, HirotoshiOhno, YasushiInada, YusukeArioka, HitoshiMorita, HajimeHida, NaoyaSugawara, MitsuhiroKatada, ChikatoshiNawata, ShuichiIshida, HirooTsuboya, AyakoTsuda, TakashiYamaguchi, TakuhiroNakajima, Takako Eguchi